Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Alisertib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Puma Biotech Initiates ALISCA™-Breast1 Phase II Trial of Alisertib
    Puma Biotech Initiates ALISCA™-Breast1 Phase II Trial of Alisertib

    20 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241120479300/en

    BUSINESSWIRE
    20 Nov 2024
    Share Share
    Puma's Alisertib Phase 1/1b Data In Advanced EGFR-Mutant Lung Cancer
    Puma's Alisertib Phase 1/1b Data In Advanced EGFR-Mutant Lung Cancer

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603691086/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    Puma's Alisertib Shows Findings In Endocrine-Resistant Metastatic Breast Cancer
    Puma's Alisertib Shows Findings In Endocrine-Resistant Metastatic Breast Cancer

    02 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240602354785/en

    BUSINESSWIRE
    02 Jun 2024
    Share Share
    Puma Alisertib Asco Abstracts: 2024 Annual Meeting Titles Published
    Puma Alisertib Asco Abstracts: 2024 Annual Meeting Titles Published

    23 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240523137578/en

    BUSINESSWIRE
    23 May 2024
    Share Share
    Puma Announces FDA Allowance to Proceed Under IND for Alisertib in Breast Cancer
    Puma Announces FDA Allowance to Proceed Under IND for Alisertib in Breast Cancer

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320193286/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Puma Bio Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib
    Puma Bio Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib

    13 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240213029980/en

    BUSINESSWIRE
    13 Feb 2024
    Share Share